PROCEPT BioRobotics Corporation
PRCTHealthcareNASDAQMedical Devices
Scan Results
Daily timeframePROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the United States and internationally. At a $1.09B market cap, PROCEPT BioRobotics Corporation ranks as a small-cap company within healthcare. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia.
Market Cap
$1.09B
Beta
0.87
P/E (TTM)
—
P/E (Fwd)
-21.57
EPS (TTM)
$-1.83
EPS (Fwd)
$-0.89
ROE
-27.8%
ROA
-13.5%
Cash
$245.6M
Total Debt
$78.0M
Free CF
-$43.2M
52W Change
-67.1%
Annual Financials
Cash vs Debt
With $245.6M in cash and $78.0M in debt, PRCT maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$43.2M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -27.8% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $75.0M (2022) to $308.1M (2025), reflecting a 311% increase over the period.
With cash comfortably exceeding debt, PRCT has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for PROCEPT BioRobotics Corporation and its sector.